Literature DB >> 29514801

Intramuscular glucocorticoid injection versus placebo injection in hip osteoarthritis: a 12-week blinded randomised controlled trial.

Desirée M J Dorleijn1, Pim A J Luijsterburg1, Max Reijman2, Margreet Kloppenburg3, Jan A N Verhaar2, Patrick J E Bindels1, Pieter Koen Bos2, Sita M A Bierma-Zeinstra1,2.   

Abstract

OBJECTIVES: Guidelines recommend intra-articular glucocorticoid injection in patients with painful hip osteoarthritis. However, intra-articular hip injection is an invasive procedure. The efficacy of systemic glucocorticoid treatment for pain reduction in hip osteoarthritis is unknown. This randomised, double-blind, trial assessed effectiveness in hip pain reduction of an intramuscular glucocorticoid injection compared with a placebo injection in patients with hip osteoarthritis.
METHODS: Patients with painful hip osteoarthritis were randomised to either 40 mg triamcinolone acetate or placebo with an intramuscular injection into the gluteus muscle. The primary outcomes were severity of hip pain at rest, during walking (0-10) and WOMAC pain at 2-week postinjection. We used linear mixed models for repeated measurements at 2, 4, 6 and 12 weeks for the intention-to-treat data analysis.
RESULTS: Of the 107 patients randomised, 106 could be analysed (52 in the glucocorticoid group, 54 in the placebo group). At 2-week follow-up, compared with placebo injection, the intramuscular glucocorticoid injection showed a significant and clinically relevant difference in hip pain reduction at rest (difference -1.3, 95% CI -2.3 to -0.3). This effect persisted for the entire 12-week follow-up. For hip pain during walking, the effect was present at 4-week, 6-week and 12-week follow-ups, and for WOMAC pain the effect was present at 6-week and 12-week follow-up.
CONCLUSIONS: An intramuscular glucocorticoid injection showed effectiveness in patients with hip osteoarthritis on one of the three primary outcomes at 2-week postinjection. All primary outcomes showed effectiveness from 4 to 6 weeks, up to a 12-week follow-up. TRIAL REGISTRATION NUMBER: NTR2966. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  corticosteroids; osteoarthritis; treatment

Mesh:

Substances:

Year:  2018        PMID: 29514801     DOI: 10.1136/annrheumdis-2017-212628

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  9 in total

Review 1.  Microbiota-assisted therapy for systemic inflammatory arthritis: advances and mechanistic insights.

Authors:  Bowen Li; Bo Yang; Xiaoming Liu; Jianxin Zhao; R Paul Ross; Catherine Stanton; Hao Zhang; Wei Chen
Journal:  Cell Mol Life Sci       Date:  2022-08-06       Impact factor: 9.207

Review 2.  Pathogenesis and clinical management of obesity-related knee osteoarthritis: Impact of mechanical loading.

Authors:  Lianzhi Chen; Jessica Jun Yi Zheng; Guangyi Li; Jun Yuan; Jay R Ebert; Hengyuan Li; John Papadimitriou; Qingwen Wang; David Wood; Christopher W Jones; Minghao Zheng
Journal:  J Orthop Translat       Date:  2020-05-15       Impact factor: 5.191

Review 3.  Therapeutic options for targeting inflammatory osteoarthritis pain.

Authors:  Philip G Conaghan; Andrew D Cook; John A Hamilton; Paul P Tak
Journal:  Nat Rev Rheumatol       Date:  2019-06       Impact factor: 20.543

4.  Effectiveness of intramuscular gluteal glucocorticoid injection versus intra-articular glucocorticoid injection in knee osteoarthritis: design of a multicenter randomized, 24 weeks comparative parallel-group trial.

Authors:  Marianne F Mol; Jos Runhaar; P Koen Bos; Desirée M J Dorleijn; Marijn Vis; Jacobijn Gussekloo; Patrick J E Bindels; Sita M A Bierma-Zeinstra
Journal:  BMC Musculoskelet Disord       Date:  2020-04-11       Impact factor: 2.362

5.  Zoledronic acid plus methylprednisolone versus zoledronic acid or placebo in symptomatic knee osteoarthritis: a randomized controlled trial.

Authors:  Guoqi Cai; Laura L Laslett; Dawn Aitken; Flavia Cicuttini; Lyn March; Catherine Hill; Tania Winzenberg; Graeme Jones
Journal:  Ther Adv Musculoskelet Dis       Date:  2019-10-23       Impact factor: 5.346

Review 6.  Intramuscular corticosteroid injections in seasonal allergic rhinitis: A systematic review.

Authors:  Ahmed B Bayoumy; Felicia van Schie; Inge Stegeman; Esther B Blijleven; Erwin L van der Veen; Jacob A de Ru
Journal:  Laryngoscope Investig Otolaryngol       Date:  2021-09-04

7.  Clinical effectiveness of one ultrasound guided intra-articular corticosteroid and local anaesthetic injection in addition to advice and education for hip osteoarthritis (HIT trial): single blind, parallel group, three arm, randomised controlled trial.

Authors:  Zoe Paskins; Kieran Bromley; Martyn Lewis; Gemma Hughes; Emily Hughes; Susie Hennings; Andrea Cherrington; Alison Hall; Melanie A Holden; Kay Stevenson; Ajit Menon; Philip Roberts; George Peat; Clare Jinks; Jesse Kigozi; Raymond Oppong; Nadine E Foster; Christian D Mallen; Edward Roddy
Journal:  BMJ       Date:  2022-04-06

8.  Effect of Intramuscular vs Intra-articular Glucocorticoid Injection on Pain Among Adults With Knee Osteoarthritis: The KIS Randomized Clinical Trial.

Authors:  Qiuke Wang; Marianne F Mol; P Koen Bos; Desirée M J Dorleijn; Marijn Vis; Jacobijn Gussekloo; Patrick J E Bindels; Jos Runhaar; Sita M A Bierma-Zeinstra
Journal:  JAMA Netw Open       Date:  2022-04-01

9.  Intra-articular injection of triamcinolone acetonide sustains macrophage levels and aggravates osteophytosis during degenerative joint disease in mice.

Authors:  Mauricio N Ferrao Blanco; Yvonne M Bastiaansen Jenniskens; Nicole Kops; Athina Chavli; Roberto Narcisi; Sander M Botter; Pieter J M Leenen; Gerjo J V M van Osch; Niamh Fahy
Journal:  Br J Pharmacol       Date:  2022-01-26       Impact factor: 9.473

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.